BIIB News 315.31 07/01/2014 04:32:14 Biogen Idec Inc (BIIB)
Post# of 273256
Posted On: 07/01/2014 5:32:09 AM
Biogen Idec Inc (BIIB) 315.31 $BIIB
Gilead Sciences Inc.'s Upcoming Catalyst(s)
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 30, 10:31PM CDT
Gilead Sciences ' blood cancer drug idelalisib is up for FDA approval for two different indications. The biotech giant should hear about the application it submitted second on or before Aug. 6. It's not scheduled to hear about the first application...
Integra Lifesciences Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:30PM CDT
On Jun 26, 2014, Zacks Investment Research downgraded Integra Lifesciences Holdings Corporation (IART) to a Zacks Rank #4 (Sell).
Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014
Business Wire - Mon Jun 30, 3:01PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report second quarter 2014 financial results on Wednesday, July 23, 2014, before the financial markets open.
Eli Lilly & Boehringer's Insulin Copy Gets Positive EU Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 12:50PM CDT
LY2963016 is the first biosimilar insulin to be recommended for approval in the EU.
Vertex Pharmaceuticals' Kalydeco Wins Positive EU Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 12:40PM CDT
EU approval for the eight additional gating mutations could provide access to 250 eligible patients.
UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.
Celladon Corporation (CLDN) Jumps: Stock Rises 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:21AM CDT
Celladon Corporation (CLDN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Discovery Laboratories Inc. (DSCO) in Focus: Stock Rises 7.83% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 7:44AM CDT
Discovery Laboratories Inc. (DSCO) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 5:00PM CDT
BioDelivery (BDSI) announced that it has completed patient enrolment for its phase III RHAPSODY study on clonidine topical gel.
Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
Brain Injury - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6zjvn6/brain_injury) has announced the addition of the "Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Biogen Idec Inc. - Acorda Therapeutics, Inc. - Chiesi Farmaceutici SpA - TetraLogic Pharmaceuticals - Virogenomics, Inc. - Faron Pharmaceuticals Oy For more information visit http://www.researchandmarkets.com/research/6z...ain_injury
Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 4:00PM CDT
Auxilium (AUXL) announced that Sobi has filed for an extension of the label for Xiapex in the EU to include the indication of Peyronie's disease.
Bristol-Myers Up on Nivolumab News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 9:45AM CDT
Bristol-Myers' (BMY) nivolumab performed very well in a late-stage study.
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 5:10PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in phase II/III study.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
British Columbia to Reimburse TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis
CNW Group - Wed Jun 25, 10:00AM CDT
Biogen Idec Canada announces today that TECFIDERATM (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver
PR Newswire - Wed Jun 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRTX, DLTR, CAR, R, and BIIB.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders
at The Street - Tue Jun 24, 9:45AM CDT
Stocks with insider trader activity include BIIB, FDS and GCO
Gilead Sciences Inc.'s Upcoming Catalyst(s)
Brian Orelli, The Motley Fool - Motley Fool - Mon Jun 30, 10:31PM CDT
Gilead Sciences ' blood cancer drug idelalisib is up for FDA approval for two different indications. The biotech giant should hear about the application it submitted second on or before Aug. 6. It's not scheduled to hear about the first application...
Integra Lifesciences Down to Sell - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 4:30PM CDT
On Jun 26, 2014, Zacks Investment Research downgraded Integra Lifesciences Holdings Corporation (IART) to a Zacks Rank #4 (Sell).
Biogen Idec to Report Second Quarter 2014 Financial Results on July 23, 2014
Business Wire - Mon Jun 30, 3:01PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report second quarter 2014 financial results on Wednesday, July 23, 2014, before the financial markets open.
Eli Lilly & Boehringer's Insulin Copy Gets Positive EU Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 12:50PM CDT
LY2963016 is the first biosimilar insulin to be recommended for approval in the EU.
Vertex Pharmaceuticals' Kalydeco Wins Positive EU Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 12:40PM CDT
EU approval for the eight additional gating mutations could provide access to 250 eligible patients.
UCB's Vimpat Positive for Partial-Onset Seizures - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 10:50AM CDT
UCB SA (UCBJF) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures.
Celladon Corporation (CLDN) Jumps: Stock Rises 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 8:21AM CDT
Celladon Corporation (CLDN) was a big mover last session, as the company saw its shares rise by over 5% on the day.
Discovery Laboratories Inc. (DSCO) in Focus: Stock Rises 7.83% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 30, 7:44AM CDT
Discovery Laboratories Inc. (DSCO) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
BioDelivery Progresses with Clonidine Late-Stage Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 5:00PM CDT
BioDelivery (BDSI) announced that it has completed patient enrolment for its phase III RHAPSODY study on clonidine topical gel.
Coronado Falls on TSO Study Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 27, 10:20AM CDT
Coronado (CNDO) announced disappointing top-line results from a pilot study on TSO.
Brain Injury - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6zjvn6/brain_injury) has announced the addition of the "Brain Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Brain Injury - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Brain Injury pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Biogen Idec Inc. - Acorda Therapeutics, Inc. - Chiesi Farmaceutici SpA - TetraLogic Pharmaceuticals - Virogenomics, Inc. - Faron Pharmaceuticals Oy For more information visit http://www.researchandmarkets.com/research/6z...ain_injury
Auxilium/Sobi's Xiapex Filed for Label Expansion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 4:00PM CDT
Auxilium (AUXL) announced that Sobi has filed for an extension of the label for Xiapex in the EU to include the indication of Peyronie's disease.
Bristol-Myers Up on Nivolumab News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 9:45AM CDT
Bristol-Myers' (BMY) nivolumab performed very well in a late-stage study.
Prothena Corporation (PRTA) Falls: Stock Goes Down 5.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:43AM CDT
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down nearly 12% since Jun 18. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future.
Isis Pharma Gets $1M Milestone Payment from Glaxo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 5:10PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $1 million milestone payment from GlaxoSmithKline pertaining to the advancement of ISIS-TTR in phase II/III study.
Ligand Pharma-TG Therapeutics Collaborate on IRAK4 Inhibitors - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 25, 3:30PM CDT
Ligand Pharmaceuticals Inc. (LGND) inked a deal with TG Therapeutics, Inc. to develop and commercialize Ligand's IRAK-4 inhibitors.
British Columbia to Reimburse TECFIDERA(TM), a First-Line Oral Treatment for Multiple Sclerosis
CNW Group - Wed Jun 25, 10:00AM CDT
Biogen Idec Canada announces today that TECFIDERATM (dimethyl fumarate) is now available for reimbursement in British Columbia (B.C.) through B.C. PharmaCare. TECFIDERATM is a first-line oral treatment for adults with relapsing-remitting multiple sclerosis (RRMS). TECFIDERATM is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the progression of disability.(1)
Critical Alerts For Vertex Pharmaceuticals, Dollar Tree, Avis, Ryder, and Biogen Released By InvestorsObserver
PR Newswire - Wed Jun 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for VRTX, DLTR, CAR, R, and BIIB.
XenoPort's XP23829 in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 3:52PM CDT
XenoPort, Inc. (XNPT) has commenced a phase II study on XP23829 for moderate-to-severe chronic plaque-type psoriasis.
Insider Trading Alert - BIIB, FDS And GCO Traded By Insiders
at The Street - Tue Jun 24, 9:45AM CDT
Stocks with insider trader activity include BIIB, FDS and GCO
(0)
(0)Scroll down for more posts ▼